Ezra Cohen to Proto-Oncogene Proteins c-ret
This is a "connection" page, showing publications Ezra Cohen has written about Proto-Oncogene Proteins c-ret.
Connection Strength
0.339
-
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016 Dec 15; 122(24):3856-3864.
Score: 0.139
-
New approaches to thyroid cancer. Clin Adv Hematol Oncol. 2012 Apr; 10(4):255-6.
Score: 0.103
-
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
Score: 0.097